Adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A single center, real-world study in China.

被引：0
|
作者：
Xu, Chongrui
Tu, Hai-Yan
Sun, Yueli
Li, Yang-Si
Xu, Bingfei
Wang, Binchao
Chen, Hua-Jun
Wang, Zhen
Zhou, Qing
Yang, Jinji
Yang, Qi
Wu, Yi-Long
机构：
[1] South China Univ Technol, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci,Sch Med, Guangzhou, Peoples R China
[2] LinkDoc Beijing Technol Co Ltd, Beijing, Peoples R China
[3] Guangdong Prov Peoples Hosp & Guangdong Acad Med, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21081
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Analysis of thromboembolic events in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: A single-center real-world study
    Kim, Tae-Hwan
    Yang, Cheongin
    Choi, Yong Won
    Kwon, Minsuk
    Lee, Hyun Woo
    Kang, Seok Yun
    Ahn, Mi Sun
    Choi, Jin-Hyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
    Miao, Kang
    Zhang, Xiaotong
    Wang, Hanping
    Si, Xiaoyan
    Ni, Jun
    Zhong, Wei
    Zhao, Jing
    Xu, Yan
    Chen, Minjiang
    Pan, Ruili
    Wang, Mengzhao
    Zhang, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] A real-world experience of immune checkpoint inhibitors: immunotherapy related adverse events for locally advanced and metastatic non-small cell lung cancer
    Sidon, L.
    Dillon, M.
    Power, D.
    Dubash, S.
    LUNG CANCER, 2020, 139 : S49 - S49
  • [4] Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors
    Hu, Xiao
    Rodday, Angie Mae
    Gurinovich, Anastasia
    Pan, Stacey
    Salei, Yana V.
    Lin, Jeffrey H.
    Byrne, Margaret M.
    Cao, Yu
    Pai, Lori
    Parsons, Susan K.
    IMMUNOTHERAPY, 2025,
  • [5] Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye
    Yavuz, Melike Yuksel
    Karapinar, Filiz
    Anar, Ceyda
    Ok, Mehdi
    Erturk, Sema
    Gayaf, Mine
    Ucsular, Fatma Demirci
    Polat, Guelru
    MEDICAL SCIENCE MONITOR, 2025, 31
  • [6] Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer
    Muchnik, Eugene
    Loh, Kah Poh
    Strawderman, Myla
    Magnuson, Allison
    Mohile, Supriya G.
    Estrah, Vered
    Maggiore, Ronald J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2019, 67 (05) : 905 - 912
  • [7] Immune checkpoint inhibitors in advanced non-small cell lung cancer: Real-world survival and safety
    Tang, Monica
    Lee, Chee
    Lewis, Craig
    Boyer, Michael
    Brown, Bernadette
    Schaffer, Andrea
    Pearson, Sallie-Anne
    Simes, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 30 - 31
  • [8] Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A real-world perspective.
    Rizwan, Saleha
    Alhamad, Khaled
    Abel, Stephen
    Bakalov, Veli
    Rodriguez, Robin Raquel
    Sethi, Ashish
    Khan, Talal
    Attah, Abraham Attah
    Yasir, Muhammad
    Shankar, Karthik
    Lo, Herman
    Friday, Andrew
    Finley, Gene Grant
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Real-world use and survival outcomes of immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Youn, Bora
    Trikalinos, Nikolaos
    Mor, Vincent
    Wilson, Ira
    Dahabreh, Issa
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Efficacy and safety of combining radiotherapy with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a real-world study
    Yang, Guanli
    Zhou, Zhen
    Liu, Chengxin
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2024, 46 (06) : 861 - 871
12345